Vertex Pharmaceuticals Incorporated (FRA:VX1)
Germany
· Delayed Price · Currency is EUR | Market Cap | 101.47B |
| Revenue (ttm) | 10.27B |
| Net Income (ttm) | -914.93M |
| Shares Out | n/a |
| EPS (ttm) | -3.55 |
| PE Ratio | n/a |
| Forward PE | 23.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1 |
| Average Volume | 222 |
| Open | 395.00 |
| Previous Close | 391.40 |
| Day's Range | 392.45 - 395.00 |
| 52-Week Range | 362.70 - 489.20 |
| Beta | n/a |
| RSI | 36.08 |
| Earnings Date | May 5, 2025 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com... [Read more]
News
Vertex Pharmaceuticals Incorporated (VRTX) Q1 2025 Earnings Call Transcript
Vertex misses on both lines in Q1 as 2025 revenue forecast narrowed
Vertex Pharmaceuticals Q1 results missed estimates, but the company raised its 2025 revenue outlook.
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period . Q1 Revenue: $2.77 billion ve...
Vertex misses quarterly results on weaker-than-expected demand for cystic fibrosis drug
Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta.
Vertex Pharmaceuticals Non-GAAP EPS of $4.06 misses by $0.23, revenue of $2.77B misses by $90M
Vertex Reports First Quarter 2025 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2025, and raised the low end of its tota...
Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues. ...
Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) will report its first-quarter earnings on Monday. As the company reports after market hours, Wall Street expects $4.32 in EPS and $2.85 billion in revenues.
Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the first quarter, after the closing bell on Monday, May 5.
Gilead and Vertex Pharma named among biotech’s tariff safe havens
Earnings Outlook For Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ: VRTX) will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex Pha...
S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” Jim Lebenthal of Cerity Partners named Berkshire Hathaway Inc. (NYSE: BRK) as his final trade ahead of its quarterly earnings report on Saturday . On April...
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group
Final Trades are in! The Investment Committee reveals their top picks to close out the daydont miss it!
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopha...
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site (FOTO)
Vienna (ots) - The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarter...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom
Trump's tariff policy is the latest uncertainty to plague the pharmaceutical sector.
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 1...
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over...
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals's (NYSE: VRTX) short percent of float has fallen 22.32% since its last report. The company recently reported that it has 4.46 million shares sold short , which is 1.74% of all ...
Mumbai-Born US CEO Reshma Kewalramani Named In TIME's 2025 Influential List
Reshma Kewalramani, the Indian-origin CEO of US-based Vertex Pharmaceuticals, has been named on the list of "100 Most Influential People" of 2025 by Time Magazine.
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF Research